Emtricitabine/Tenofovir Disoproxil Fumarate

恩曲他滨/富马酸替诺福韦二吡呋酯

Report date: 2026/03/13 20:02:36

Base Information

Drug NameEmtricitabine/Tenofovir Disoproxil Fumarate
Drug Alias Name恩曲他滨富马酸替诺福韦二吡呋酯Tenofovir Disoproxil Fumarate and EmtricitabineEmtricitabine - tenofovir disoproxil mixtEmtricitabine and Tenofovir Disoproxil FumarateEmtricitabine/tenofovir +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsMedication AdherenceAmphetamine-Related DisordersSubstance-Related Disorders +[8] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2004/08/02
Country/TerritoryBotswanaUnited StatesUganda +[17] 
CombinationsYes EmtricitabineTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalJapan Tobacco (Hong Kong) LtdGilead Sciences Inc +[7] 
Inactive CompaniesPublic Health Foundation Enterprises IncUniversity Of ManitobaFriends Research Institute Inc +[8] 
Active IndicationsSubstance-Related DisordersHIV Infections
Inactive IndicationsMedication AdherenceAmphetamine-Related DisordersHepatitis B, Chronic +[6] 

Other Information

ATC CodeJ05AR03
Related LinksWikipediaKEGG